Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.